Capricorn Fund Managers Ltd purchased a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 868,417 shares of the company’s stock, valued at approximately $13,643,000. Takeda Pharmaceutical comprises 4.9% of Capricorn Fund Managers Ltd’s portfolio, making the stock its 6th biggest position.
Several other large investors also recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Takeda Pharmaceutical by 171.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 3,904,296 shares of the company’s stock worth $60,907,000 after purchasing an additional 2,465,178 shares during the last quarter. Federated Hermes Inc. grew its holdings in Takeda Pharmaceutical by 106.7% in the 1st quarter. Federated Hermes Inc. now owns 601,629 shares of the company’s stock valued at $9,915,000 after buying an additional 310,512 shares in the last quarter. Sequoia Financial Advisors LLC increased its stake in shares of Takeda Pharmaceutical by 8.7% in the 1st quarter. Sequoia Financial Advisors LLC now owns 21,189 shares of the company’s stock worth $349,000 after acquiring an additional 1,692 shares during the last quarter. SYSTM Wealth Solutions LLC purchased a new position in shares of Takeda Pharmaceutical during the 4th quarter worth $192,000. Finally, Seven Eight Capital LP acquired a new position in shares of Takeda Pharmaceutical during the 4th quarter valued at about $181,000. Hedge funds and other institutional investors own 2.65% of the company’s stock.
Takeda Pharmaceutical Price Performance
TAK stock opened at $16.32 on Tuesday. Takeda Pharmaceutical Company Limited has a 52-week low of $12.28 and a 52-week high of $17.15. The company has a quick ratio of 0.56, a current ratio of 0.99 and a debt-to-equity ratio of 0.63. The stock has a market cap of $51.65 billion, a price-to-earnings ratio of 22.67, a price-to-earnings-growth ratio of 7.34 and a beta of 0.62. The business has a fifty day moving average of $15.38 and a two-hundred day moving average of $15.96.
Wall Street Analysts Forecast Growth
Separately, JPMorgan Chase & Co. cut their price objective on shares of Takeda Pharmaceutical from $14.20 to $14.00 in a research report on Friday, September 1st.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
- Five stocks we like better than Takeda Pharmaceutical
- What is the Nikkei 225 index?
- 2 Beauty Stocks Beaten By the Ugly Stick But Ready to Rally
- How to Invest in the FAANG Stocks
- Got Nuclear? Three Stocks To Play Energy’s Next Frontier
- What Are Meme Stocks and Are They Viable Investments?
- The Top 4 Utilities for Value, Yield, and Upside Potential
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.